The medical world has come a long way from the traditional centralized way of conducting clinical trials, but there is still much to be done to modernize. curebase provides the infrastructure—physical and digital—for distributed clinical trials and will double its success with a new $40 million funding round.
Clinical trials were usually conducted in one or more institutions, such as research hospitals or large medical centers. As more drugs and treatments need to be tested, it has become necessary to spread out a bit and conduct trials in a dozen or more locations.
The problem is obvious: how to synchronize practices and data between dozens or even hundreds of different institutions, laboratories, regions, and so on? Curebase combines the app-based patient experience with a controlled and standardized provider-side process to ensure that the data in a decentralized study is as good as one-place study.
“There are indeed traditional trials with 500 sites – it’s just so hard to reach patients and it’s incredibly expensive. Not many of them use integrated platforms, you have everything on paper, the data is not visible,” explained CEO and co-founder Tom Lemberg. “Our patient experience makes it easy to participate in the study—any patient, anywhere, can participate in the study at home and with their physician.”
But it’s more than just a handy app – Curebase needs to dig deeper into the system to make sure everything is working properly and that a given test, such as a CT scan or lab analysis, is consistent across sites.
“We don’t just throw software over the fence and say, ‘Here, go figure it out,’ we work from start to finish,” Lemberg said. “We put trained principal investigators in charge of each study. We see every site, who does what, incredible data transparency.”
Clearly, there is value here, as the company has achieved significant growth (it has conducted 50 studies so far, with the number of studies tripling or more every year in existence) and has now raised significant strategic funding from pharmaceutical company Gilead.
“We believe that by taking a human-centered approach to design and technology, as Curebase does, we can co-design a process that delivers treatment options to people in need more effectively,” said Matt Bryant, head of technology and innovation at Gilead. in a press release.
The funding will allow further expansion of Curebase as a whole, activating partnerships with more institutions and hiring the people needed to oversee trials in which they will be used. Lemberg said they also hope to expand with new data sources such as heart rate smartwatches and improve the field presence they maintain at partner institutions.
He also said that by the end of the year they plan to exit the US, Canada, UK and France for six more companies in Europe and a total of 10 languages (presumably those spoken in selected countries).
Credit: techcrunch.com /